- Home
- DJT vs OGN Comparison
DJT vs OGN Comparison
Compare DJT & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DJT
- OGN
- Stock Information
- Founded
- DJT 2021
- OGN 1923
- Country
- DJT United States
- OGN United States
- Employees
- DJT N/A
- OGN N/A
- Industry
- DJT Computer Software: Programming Data Processing
- OGN Biotechnology: Pharmaceutical Preparations
- Sector
- DJT Technology
- OGN Health Care
- Exchange
- DJT Nasdaq
- OGN Nasdaq
- Market Cap
- DJT 5.0B
- OGN 4.0B
- IPO Year
- DJT N/A
- OGN N/A
- Fundamental
- Price
- DJT $18.80
- OGN $14.76
- Analyst Decision
- DJT
- OGN Hold
- Analyst Count
- DJT 0
- OGN 5
- Target Price
- DJT N/A
- OGN $20.80
- AVG Volume (30 Days)
- DJT 3.8M
- OGN 4.1M
- Earning Date
- DJT 05-25-2025
- OGN 05-01-2025
- Dividend Yield
- DJT N/A
- OGN 7.72%
- EPS Growth
- DJT N/A
- OGN N/A
- EPS
- DJT N/A
- OGN 3.33
- Revenue
- DJT $3,618,800.00
- OGN $6,403,000,000.00
- Revenue This Year
- DJT N/A
- OGN N/A
- Revenue Next Year
- DJT N/A
- OGN $1.52
- P/E Ratio
- DJT N/A
- OGN $4.36
- Revenue Growth
- DJT N/A
- OGN 2.23
- 52 Week Low
- DJT $11.75
- OGN $13.87
- 52 Week High
- DJT $61.00
- OGN $23.10
- Technical
- Relative Strength Index (RSI)
- DJT 37.49
- OGN 40.58
- Support Level
- DJT $19.62
- OGN $14.81
- Resistance Level
- DJT $23.97
- OGN $14.81
- Average True Range (ATR)
- DJT 1.05
- OGN 0.47
- MACD
- DJT 0.39
- OGN -0.09
- Stochastic Oscillator
- DJT 23.05
- OGN 11.44
About DJT Trump Media & Technology Group Corp. Common Stock
Trump Media & Technology Group Corp is a media and technology company rooted in social media, digital streaming, information technology infrastructure, and more. Its initial product launch will focus on its social media platform, Truth Social, which encourages an open, free, and honest conversation without discriminating against political ideology.
About OGN Organon & Co.
Organon & Co is a science-based global pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars, and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.